Drugs / HR070803
HR070803
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04796948 | Apr 2021 → Jun 2024 | malignant pancreatic neoplasm | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT06383078 | Apr 2024 → Mar 2027 expected | — | The First Affiliated Hospital with Nanjing Medical University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05425472 | Jul 2022 → Jan 2023 | esophageal cancer | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT05945901 | Aug 2023 → Dec 2025 overdue | colorectal cancer | Jiangsu HengRui Medicine Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT06217042 | Feb 2024 → Mar 2027 expected | malignant pancreatic neoplasm | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT05751850 | Jun 2023 → Dec 2024 | — | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
Press releases naming this drug 2 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HR070803 | “Phase 1 trial of HR070803 (an Irinotecan liposome) in combination with 5-fluorouracil, leucovorin, and oxaliplatin for untreated advanced or metastatic pancreatic ductal adenocarcinoma.” PMID 40619376 ↗ Jul 2025 |
| Known as | Irinotecan liposome | “Phase 1 trial of HR070803 (an Irinotecan liposome) in combination with 5-fluorouracil, leucovorin, and oxaliplatin for untreated advanced or metastatic pancreatic ductal adenocarcinoma.” PMID 40619376 ↗ Jul 2025 |
| Known as | liposomal irinotecan | “BACKGROUND: This study assessed the safety, preliminary antitumor activity, and pharmacokinetics of HR070803 (a novel liposomal irinotecan) in combination with 5-FU/LV and...” PMID 40619376 ↗ Jul 2025 |
| Route | Intravenous | “HR070803 monotherapy will be administered by intravenous infusion” NCT05425472 ↗ |